Davies, Karen Brown, Dimitris Papamargaritis Diabetes, Obesity and Metabolism.2025
Disclosures: Majd Aboona: Nothing to Disclose, Leith Ghani: Nothing to Disclose, Pooja Rangan: Nothing to Disclose, Vincent Chen: AstraZeneca: site PI on industry-sponsored trial, Ipsen: site co-I on industry-sponsored trial, Kowa: site co-I on industry-sponsored trial, Cheng Han Ng: Nothing to Disclose, Daniel Huang: Nothing to Disclose, Mark Muthiah: Lerna Bio: Stock privately held company, Olympus: Speaking and Teaching, Boston Scientific: Speaking and Teaching, Novo Nordisk: Grant/Research Support, Echosens: Grant/Research Support, Gilead: Advisor, Donghee Kim: Nothing to Disclose, Moises Nevah Rubin: Nothing to Disclose, Ma Ai Thanda Han: Nothing to Disclose, Michael Fallon: Nothing to Disclose, Karn Wijarnpreecha: Nothing to Disclose 1123 RISK OF COMORBID MENTAL HEALTH CONDITIONS IN CHILDREN WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Sheila Noon 1 Nhat Thai 2 Kimberly Newton 3 Nidhi Goyal 3 Benjamin Maxwell 3 Elizabeth Yu 3 Warren Shapiro 4 Jeffrey Schwimmer 3 , 1 University of California, San Diego School of Medicine, 2 San Diego State University, 3 Rady Children's Hospital San Diego, 4 Kaiser Permanente San Diego Background: Steatotic liver disease (SLD) affects nearly 1 in 10 children in the United States
Unintentional weight loss beyond your treatment goals requires assessment
Our agents serve Tamarac, Deerfield Beach, Greenacres, Port St
The results: Tirzepatide group : Average weight loss of 20.2% Semaglutide group : Average weight loss of 13.7% Difference : Tirzepatide users lost approximately 47% more weight What this means in real terms : For a 220-pound person, Mounjaro might help you lose about 44-49 pounds, compared to 30-33 pounds with Ozempic a difference of roughly 14-16 additional pounds
